



October 28, 2022

To
National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India

To
BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India

Subject : Amendment to the Limited Liability Partnership Agreement entered into by the Company with respect to HCG NCHRI Oncology LLP, subsidiary of the Company.

Reference: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Script Code : NSE Scrip Code: HCG; BSE Scrip Code: 539787

Dear Sir/Madam,

This is to inform you that the Company has executed an amendment agreement to the Limited Liability Partnership Agreement dated March 20, 2017 (“LLP Agreement”), with Nagpur Cancer Hospital and Research Institute Private Limited (“NCHRI”) and Dr. Ajay Mehta, on October 27, 2022 (“Amendment Agreement”) amending the capital contribution proportion in HCG NCHRI Oncology LLP (“LLP”), as partners of the LLP.

As per the Amendment Agreement, the Company, NCHRI, and Dr Ajay Mehta shall contribute to the Capital of the LLP, as partners, in the proportion of 87.14: 5.44: 7.42, respectively. Prior to the amendment, the Capital contribution of the Company, NCHRI, and Dr Ajay Mehta in the LLP was in the proportion of 76:8:16, respectively.

All other terms of the LLP Agreement, remains unchanged.

Kindly take this on record.

Thanking you,
For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489